Dr Reddy's Laboratories share price plunged 6.66 per cent at Rs 1,203.50 per share on the NSE in Friday's intraday deals after analysts remained cautious on the company's Q3 performance ...

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine ...

Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Although Dr Reddy's Laboratories' Q3 earnings slightly exceeded analysts' expectations, the main point of concern was the ...

The company's North American revenue has seen a decline of over 9%. One of the primary worries is the reduction in revenues ...

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1 (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Revlimid has arguably been the single biggest growth driver for Dr Reddy's in recent years, fueling record-high US sales last ...

Revlimid is a medicine used to treat certain cancers and serious conditions affecting blood cells and bone marrow.

Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.

Indian shares closed lower on Friday after a choppy session. Markets gave up early gains as concerns about slowing earnings growth ...

Indian shares were subdued on Friday after U.S. President Donald Trump reiterated his firm stance on tariffs. At the World Economic ...